UNM Scientist Studies Where Brain Cancer Cells Hide and How to Fight Them
May 4, 2026
https://medtechspectrum.com/news/40/25517/unm-scientist-studies-where-brain-cancer-cells-hide-and-how-to-fight-them.html
https://medtechspectrum.com/news/40/25517/unm-scientist-studies-where-brain-cancer-cells-hide-and-how-to-fight-them.html
Scientists have developed a way to turn the body’s own immune cells into cancer-fighting agents—without removing them from the body—by using red blood cells to deliver genetic instructions.
A first-in-human clinical trial led by an international team of researchers and published in the New England Journal of Medicine found that setidegrasib, an investigational targeted therapy drug designed to eliminate a key cancer-driving protein called KRAS G12D, shows encouraging early activity in patients with advanced lung and pancreatic cancers.
The U.S. Food and Drug Administration has approved Merck’s Idvynso (doravirine/islatravir), a new, once-daily, two-drug single tablet for the treatment of HIV-1 infection in adults to replace the current antiretroviral regimen in those who are virologically suppressed (HIV-1 RNA <50 copies per mL).
Establishing it as the first ever reusable intermittent urinary catheter system and creating a new device classification in an industry that exclusively relied on single-use catheters for decades
Alzheimer’s disease agitation could mean peak sales of over $2.1 billion for Axsome’s Auvelity, according to analysts at William Blair.
The TAVVE study will begin later this year with ten patients, whose 30-day safety results will be submitted to the FDA.
New research out of VCU Massey Comprehensive Cancer Center has uncovered a targeted cancer therapy that significantly prevents leukemia progression, improves survival rates and minimizes damage to surrounding healthy tissue.
Led by researchers from Heidelberg Faculty of Medicine at Heidelberg University and the University of California, San Francisco (U.S.), an international team has evaluated a novel approach for the diagnosis of tuberculosis.
A research team led by Director Myung Kyungjae at the Center for Genomic Integrity within the Institute for Basic Science (IBS), in collaboration with Lee Joo-Yong (Chungnam University) has now uncovered a new strategy to overcome this resistance. T